Validity of the Control Preferences Scale in patients with emotional disorders

Figures & data

Table 1 ANOVA among three groups of participation preferences in medical decision-making in different sociodemographical, attitudes to drugs, shared decision-making, and locus of control variables

Variables	Preference group	Mean	SD	F	P-value	η^2
Age (years)	Active	45.51	12.45	23.31	0.000	0.047
	Collaborative	47.96	12.88
	Passive	54.11	14.51
Treatment duration (months)	Active	113.65	109.32	4.80	0.008	0.010
	Collaborative	105.46	106.44
	Passive	130.69	123.39
Number of different drugs	Active	2.80	1.61	0.84	0.433	0.002
	Collaborative	2.96	1.34
	Passive	3.04	1.41
DAI	Active	1.72	4.61	7.60	0.001	0.016
	Collaborative	3.79	4.04
	Passive	3.43	4.11
SDM-Q-9	Active	17.25	11.09	12.61	0.000	0.026
	Collaborative	21.68	11.13
	Passive	18.14	10.53
MHLC internal	Active	24.74	8.06	0.49	0.612	0.001
	Collaborative	24.54	7.19
	Passive	24.05	7.41
MHLC external	Active	38.54	8.55	4.62	0.010	0.010
	Collaborative	40.92	8.96
	Passive	42.12	8.88
MHLC chance	Active	14.82	5.99	2.50	0.083	0.005
	Collaborative	14.59	6.75
	Passive	15.70	7.07
MHLC doctors	Active	13.54	4.53	10.25	0.000	0.021
	Collaborative	15.45	3.15
	Passive	15.51	3.32
MHLC others	Active	10.18	3.32	1.14	0.320	0.002
	Collaborative	10.88	3.72
	Passive	10.92	3.59

Abbreviations: ANOVA, analysis of variance; DAI, drug attitudes inventory; MHLC, Multidimensional Health Locus of Control Questionnaire; P, probability; SD, standard deviation; SDM-Q-9, nine-item Shared Decision-Making Questionnaire.